city New Delhi India city Pune city Oxford covid-19 testing pandemic vaccine city New Delhi India city Pune city Oxford

Even at 62% efficacy, Covishield may be a good bet for resource-constrained India to combat pandemic

Reading now: 341
www.livemint.com

NEW DELHI: Controversy over AstraZeneca plc's covid-19 vaccine clinical trial may allow Serum Institute of India to only receive regulatory clearance for its full-dose regimen which had 62% efficacy, but that may still help India and other resource-constrained countries combat the pandemic.Serum Institute is manufacturing up to one billion doses of the vaccine, which has been jointly developed by AstraZeneca and University of Oxford.

The Pune-based firm will market the vaccine under its brand Covishield after receiving regulatory approval.“You may have a vaccine of 95% efficacy but you can give it to less than 50% of people who should be getting it, then that’s no good.

Read more on livemint.com
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News

DMCA